Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (PCYC-04753)

This study has been completed.
Information provided by (Responsible Party):
Pharmacyclics Identifier:
First received: February 20, 2009
Last updated: May 21, 2013
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2012
  Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):